The Relationship between the VEGF Levels and VEGF mRNA Expression and Clinical Course in Different Glomerulonephritis

Figures & data

Table 1 The diagnosis of renal biopsy

Proliferative glomerulonephritis (GN)	20
AA amyloidosis	6
Chronic sclerosing GN	6
Others^†	8
Undiagnosed	5

*Mesangioproliferative (6), membranoproliferative (6), and diffuse proliferative (8).

^†Diabetic nephropathy, malign nephrosclerosis, minimal change disease, cresentic glomerulonephritis, acute cellular rejection.

Table 2 Demographic and biochemical findings at baseline and 3, 6, and 12 months

	Months
	Baseline	Three months	Six months	Twelve months
SBP (mmHg)	132.69 ± 4.367	144.00 ± 5.00	132.73 ± 4.63	133.75 ± 4.46
DBP (mmHg)	82.69 ± 2.59	86.00 ± 32.1	84.32 ± 2.76	85.88 ± 2.28
Hct %	33.29 ± 1.39	33.50 ± 1.64	36.03 ± 1.21	36.62 ± 2.01
WBC	8315.51 ± 973.25	10500.05 ± 973.25	9669.00 ± 632.59	9398.75 ± 738.28
BUN (mg/dL)	40.07 ± 30.51	41.60 ± 42.27	23.15 ± 12.53	25.97 ± 12.59
Cr (mg/dL)	2.39 ± 2.30	2.16 ± 2.11	1.52 ± 1.23	1.8 ± 1.89
Ccr (mL/min)	51.35 ± 32.58	54.82 ± 55.42	76.61 ± 37.35	64.66 ± 25.70
Daily proeinuria (g/day)	3.33 ± 2.41	2.62 ± 3.19	1.35 ± 1.97	1.07 ± 1.56
ESR (mm/h)	56.21 ± 31.32	41.08 ± 36.92	22.93 ± 18.04	17.09 ± 12.67
Glucose (mg/dL)	96.17 ± 21.86	101.46 ± 37.63	90.00 ± 16.01	31.34 ± 16.98
S.Alb (g/dL)	3.15 ± 0.36	3.68 ± 0.72	3.95 ± 0.82	3.94 ± 0.77

Figure 1. PBMNC VEGF mRNA expression and serum/urine VEGF levels in patients and controls.

Figure 2. The ratio of urine VEGF/urine creatinine levels in patients and controls.

Table 3 PBMNC VEGF mRNA expression and serum/urine VEGF levels in patients and controls

		Mean	Median	Range
Serum VEGF	Patient	533.046 ± 485.0676	324.00	107.5–2177.0
	Control	412.51 ± 67.00	306.40	116.8–791.9
Urine VEGF	Patient	558.67 ± 578.69	325.40	41–4376
	Control	490.88 ± 91.534	629.50	95–851
PBMNC VEGF mRNA	Patient	159.17 ± 162.791	14.10	0–275
	Control	122.55 ± 55.31	15.00	0–490
Urine VEGF/urineCr	Patient	6.13 ± 5.55	4.8150	0.30–19.41
	Control	3.15 ± 2.89	1.6650	1.51–10.50

Table 4 Baseline and serial serum and urine VEGF and PBMNC mRNA levels in six of the patients whose proteinuria disappeared in follow-up period

	Baseline	Resolution
Serum VEGF	365.400 ± 110.92	422.90 ± 205.80
Urine VEGF	747.00 ± 488.29	890.50 ± 1135.32
PBMC VEGF mRNA	141.35 ± 162.02	102.33 ± 112.70

*Statistically important difference between baseline and resolution period.

Table 5 The serum and urine VEGF levels and PBMNC mRNA expression according to the glomerular sclerosis, tubulointerstitial nephritis (TIF), periglomerular fibrosis, and mesangial cell proliferation

		Serum VEGF	Urine VEGF	PBMNC VEGFmRNA
Glomeruler sclerosis	(+)	468.46 ± 315	409.42 ± 370.23	83.38 ± 133,47
	(−)	472.25 ± 393.03	610.78 ± 326.34	174.97 ± 174.85
		p > 0.05	p > 0.05	p > 0.05
TIF	(+)	454.16 ± 253.92	554.53 ± 469.52	55.57 ± 89.97
	(−)	483.34 ± 401.43	466.27 ± 298.85	154.14 ± 182.20
		p > 0.05	p > 0.05	p > 0.07
Periglomerular fibrosis	(+)	414.30 ± 272.94	522.15 ± 203.57	188.00 ± 9.89
	(−)	455.509 ± 352.53	493.27 ± 383.13	118.58 ± 162.99
		p > 0.05	p > 0.05	p > 0.05
Mesangial cell proliferation	(+)	417.15 ± 253.82	513.36 ± 382.77	142.63 ± 167.79
	(−)	558.867 ± 547	447.79 ± 350	74.94 ± 107.15
		p > 0.05	p > 0.05	p > 0.07